专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明专利

PL382401A1 Przeciwciała anty-CD154 未知
公开(公告)号：PL382401A1
公开(公告)日：2007-09-03
申请号：PL38240105
申请日：2005-07-26
申请人： BIOGEN IDEC INC
发明人： VAN VLIJMEN HERMAN , LUGOVSKOY ALEXY ALEXANDROVIC , HANF KARL J M
IPC分类号： C07K16/28 , A61K39/395

33. 发明专利

AU2012258386B2 Anti-alpha v beta 6 antibodies and uses thereof 未知
公开(公告)号：AU2012258386B2
公开(公告)日：2014-08-07
申请号：AU2012258386
申请日：2012-11-26
申请人： BIOGEN IDEC INC
发明人： VIOLETTE SHELIA M , KOOPMAN LOUISE A , SIMON KENNETH J , WEINREB PAUL H , VAN VLIJMEN HERMAN , SALDANHA JOSE , LUGOVSKOY ALEXEY A
IPC分类号： C07K16/00 , A61K39/395 , C07H21/04 , C12P21/04 , C12P21/08 , G01N33/53 , G01N33/574
摘要： Abstract The present invention is in the fields of cell biology, immunology and oncology. Specifically, the invention relates to humanized antibodies that recognizes v6 integrins which comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also relates to processes for their preparation, to phannaceutical compositions comprising them and to methods of treating various diseases by administering humanized anti-v6 antibodies. The invention also relates to the identification of differential expression of the integrin av36 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tunor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin av86.

34. 发明专利

EA016342B1 АНТИ-αβ-АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ 未知
公开(公告)号：EA016342B1
公开(公告)日：2012-04-30
申请号：EA200800278
申请日：2006-07-10
申请人： BIOGEN IDEC INC
发明人： VIOLETTE SHELIA , KOOPMAN LOUISE A , SIMON KENNETH J , WEINREB PAUL H , VAN VLIJMEN HERMAN , SALDANHA JOSE , LUGOVSKOY ALEXEY A
IPC分类号： C12P21/08 , A61K39/395 , A61P19/04 , A61P35/00 , A61P43/00 , C07H21/04 , C07K16/00 , C12P21/04 , G01N33/53 , G01N33/574
摘要： Данноеизобретениеотноситсяк клеточнойбиологии, иммунологиии онкологии. Этоизобретениеобеспечиваетгуманизированныеантитела, которыеузнаютинтегриныαβ, причемэтиантителасодержатвариабельнуюобласть, происходящуюизнечеловеческогоантитела, ипоменьшеймеречастьиммуноглобулина, происходящуюизантителачеловека. Данноеизобретениеобеспечиваеттакжеспособыполучениятакихантител, фармацевтическиекомпозиции, содержащиеих, испособылечения, диагностикии/илипредупрежденияразличныхзаболеванийи нарушенийпутемвведениягуманизированныханти-αβ-антителсогласноизобретению. Этоизобретениеотноситсятакжек идентификациидифференциальнойэкспрессииинтегринаαβнаповерхностяхопухолевыхклетоки тканей, применениюэтойдифференциальнойэкспрессиив определенииметастатическогопотенциалаопухолевыхклетоки способамдиагностикии лечения/предотвращенияметастазированияопухолей, атакжеэлиминацииоставшихсяметастатическихопухолевыхклетокс использованиемлигандов, вчастностиантител, которыесвязываютсяс интегриномαβ.

35. 发明专利

NZ580688A METHOD OF DESIGNING ALTERED ANTIBODIES HAVING IMPROVED ANTIGEN-BINDING AFFINITY 未知
公开(公告)号：NZ580688A
公开(公告)日：2012-03-30
申请号：NZ58068804
申请日：2004-07-26
申请人： BIOGEN IDEC INC , MASSACHUSETTS INST TECHNOLOGY
发明人： VAN VLIJMEN HERMAN , SHERMAN BRIAN WOODY H
IPC分类号： G06G7/60 , A61K39/395 , C07K16/00 , C07K16/28 , G06F19/00 , G06F19/16 , G06F19/18
摘要： Provided is a method of increasing the antigen-binding affinity of an antibody, wherein one or more steps of said method is computer-assisted, the method comprising: (i) determining a spatial representation of an optimal charge distribution of the amino acids of the antibody, with constraints imposed to represent amino acid side chain characteristics, and the associated change in binding free energy of the antibody when bound to an antigen in a solvent; (ii) identifying at least one candidate amino acid residue position of the antibody to be modified to alter the binding free energy of the antibody when bound to the antigen based on a potential gain in electrostatic binding free energy as determined in step (i); (iii) selecting an elected amino acid residue for substitution with a replacement amino acid at said candidate amino acid residue position; (iv) wherein said elected amino acid residue is selected from the group consisting of: (a) a residue that becomes partially buried upon binding; (b) a polar residue that becomes buried upon binding; and ( c) a surface residue on the antibody that is in a region of uncomplimentary potentials; (v) calculating the change in the free energy of binding of the antibody containing the modified amino acid or alteration when bound to the antigen as compared to the antibody without the modified amino acid or alteration when bound to the antigen by modelling in silica, wherein a reduction in the free energy of binding of the antibody containing the modified amino acid or alteration as compared to the antibody without the modified amino acid or alteration indicates an increase in antigen-binding affinity, wherein said step utilizes response continuum modelling in determining electrostatic binding energy; and (vi) substituting the elected amino acid residue at the candidate amino acid residue position with a replacement amino acid which closely matches the constraints imposed in step (i) by introducing a mutation into a DNA molecule encoding the antibody, thereby increasing the antigen-binding affinity of the antibody.

36. 发明专利

SG173313A1 CRIPTO BINDING MOLECULES 未知
公开(公告)号：SG173313A1
公开(公告)日：2011-08-29
申请号：SG2011045259
申请日：2006-01-05
申请人： BIOGEN IDEC INC
发明人： GLASER SCOTT , VAN VLIJMEN HERMAN , LUGOVSKOY ALEXEY ALEXANDROVICH , SANICOLA-NADEL MICHELE , WU XIUFENG , GARBER ELLEN , SALDANHA JOSE WILLIAM
摘要： CRIPTO BINDING MOLECULESHumanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g. fill-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.No Figure.

37. 发明专利

EA014226B1 АНТИТЕЛА К CD154, ИХ ФРАГМЕНТЫ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ И ФРАГМЕНТОВ 未知
公开(公告)号：EA014226B1
公开(公告)日：2010-10-29
申请号：EA200700136
申请日：2005-07-26
申请人： BIOGEN IDEC INC
发明人： VAN VLIJMEN HERMAN , LUGOVSKOY ALEXEY ALEXANDROVICH , HANF KARL J M
IPC分类号： A61K39/395 , C07K16/28
摘要： Данноеизобретениеотноситсяк антителамилиихфрагментам, содержащимпоменьшеймереоднуаминокислотнуюзаменув сравнениис антителом 5с8 дикоготипа. Данноеизобретениеотноситсятакжек композициями применениюантителпоизобретениюилиихфрагментовдлялеченияу субъектазаболеванийилинарушений, ассоциированныхс CD154.

38. 发明专利

CZ200755A3 Peptidy protilátek anti-CD154 未知
公开(公告)号：CZ200755A3
公开(公告)日：2007-04-11
申请号：CZ200755
申请日：2005-07-26
申请人： BIOGEN IDEC INC
发明人： VAN VLIJMEN HERMAN , LUGOVSKOY ALEXEY ALEXANDROVIC , HANF KARL J M
IPC分类号： A61K39/395 , A61P39/00 , C07K16/28
摘要： Resení poskytuje peptidy a jejich fragmenty, a také protilátky a jejich fragmenty, které obsahují peptidy podle resení nebo jejich fragmenty, pricemzpeptidy podle resení obsahují alespon jednu substituovanou aminokyselinu ve srovnání s protilátkou 5c8 divokého typu. Resení se dále týká kompozic a léku k lécení nemocí a poruch souvisejících s CD154.

39. 发明专利

CA2600929A1 METHODS OF HUMANIZING IMMUNOGLOBULIN VARIABLE REGIONS THROUGH RATIONAL MODIFICATION OF COMPLEMENTARITY DETERMINING RESIDUES 未知
公开(公告)号：CA2600929A1
公开(公告)日：2006-09-14
申请号：CA2600929
申请日：2006-03-06
申请人： BIOGEN IDEC INC
发明人： SIMON KENNETH , VAN VLIJMEN HERMAN , HANF KARL , LI YOU , LUGOVSKOY ALEXEY ALEXANDROVICH
IPC分类号： C07K16/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式